Masimo Corporation $MASI Shares Purchased by Amalgamated Bank

Amalgamated Bank increased its holdings in shares of Masimo Corporation (NASDAQ:MASI) by 5.2% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 21,743 shares of the medical equipment provider’s stock after acquiring an additional 1,081 shares during the period. Amalgamated Bank’s holdings in Masimo were worth $3,658,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Twin Tree Management LP acquired a new position in Masimo during the first quarter worth $29,000. Hilltop National Bank purchased a new stake in Masimo during the second quarter worth $37,000. Anderson Financial Strategies LLC purchased a new stake in Masimo during the first quarter worth $49,000. Quarry LP boosted its position in Masimo by 253.5% during the first quarter. Quarry LP now owns 449 shares of the medical equipment provider’s stock worth $75,000 after purchasing an additional 322 shares in the last quarter. Finally, GAMMA Investing LLC boosted its position in Masimo by 58.4% during the first quarter. GAMMA Investing LLC now owns 738 shares of the medical equipment provider’s stock worth $123,000 after purchasing an additional 272 shares in the last quarter. Institutional investors and hedge funds own 85.96% of the company’s stock.

Insiders Place Their Bets

In other Masimo news, Director William R. Jellison bought 3,000 shares of Masimo stock in a transaction that occurred on Monday, August 11th. The shares were purchased at an average cost of $145.98 per share, for a total transaction of $437,940.00. Following the completion of the transaction, the director owned 4,790 shares of the company’s stock, valued at $699,244.20. This represents a 167.60% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 9.70% of the company’s stock.

Analysts Set New Price Targets

MASI has been the topic of a number of research analyst reports. Piper Sandler boosted their target price on Masimo from $200.00 to $210.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 6th. Zacks Research downgraded Masimo from a “strong-buy” rating to a “hold” rating in a research report on Friday, October 24th. BTIG Research reiterated a “buy” rating and set a $198.00 target price on shares of Masimo in a research report on Thursday, September 11th. Wall Street Zen upgraded Masimo from a “hold” rating to a “buy” rating in a research report on Tuesday, October 14th. Finally, Weiss Ratings reissued a “sell (d)” rating on shares of Masimo in a report on Wednesday, October 8th. Five analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $194.60.

Masimo Stock Performance

NASDAQ MASI opened at $140.65 on Monday. Masimo Corporation has a fifty-two week low of $133.70 and a fifty-two week high of $194.88. The stock has a market cap of $7.64 billion, a price-to-earnings ratio of -16.51 and a beta of 1.28. The business has a fifty day moving average of $144.80 and a 200-day moving average of $154.12. The company has a quick ratio of 1.61, a current ratio of 2.14 and a debt-to-equity ratio of 0.57.

Masimo (NASDAQ:MASI) last released its quarterly earnings results on Thursday, June 20th. The medical equipment provider reported $1.42 earnings per share for the quarter. Masimo had a positive return on equity of 26.54% and a negative net margin of 24.85%.The company had revenue of $617.00 million during the quarter. As a group, analysts predict that Masimo Corporation will post 4.1 earnings per share for the current fiscal year.

Masimo Company Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.